Immune Mechanisms in Diabetic Nephropathy

Diabetic nephropathy arises from a complex interplay between metabolic dysregulation and chronic immune activation within the kidney. Persistent hyperglycaemia and accumulation of advanced glycation end-products generate reactive oxygen species and trigger pattern-recognition receptors on resident glomerular and tubular cells. This initiates NF-κB-mediated transcription of cytokines and chemokines that recruit innate immune cells—principally macrophages, dendritic cells and neutrophils—and activate the NLRP3 inflammasome, leading to pyroptotic death of podocytes and tubular epithelial cells. Adaptive immunity further amplifies injury through T-cell infiltration, with Th1, Th17 and cytotoxic subsets releasing interferon-γ, interleukin-17 and other mediators that potentiate mesangial expansion and extracellular matrix deposition. The resulting fibrosis and capillary rarefaction culminate in albuminuria and progressive loss of glomerular filtration rate. Emerging interventions aim to disrupt these inflammatory cascades via cytokine blockade, complement inhibition, immunoregulatory cell therapy and adjunctive metabolic therapies, offering hope for reducing the global burden of end-stage renal disease.

Research from Nature Portfolio

A foundational investigation into interleukin-17 signalling demonstrated that genetic deletion or antibody neutralisation of IL-17 markedly reduces albuminuria, glomerular damage and renal fibrosis in experimental diabetes models. These studies revealed that IL-17 synergises with hyperglycaemia to enhance NF-κB-driven expression of pro-inflammatory and pro-fibrotic genes in both podocytes and tubular epithelial cells. By attenuating macrophage infiltration and downregulating chemokine release, IL-17 blockade emerges as a promising strategy for interrupting the chronic inflammatory cycle underpinning diabetic nephropathy.

Immune Mechanisms in Diabetic Nephropathy publication trend

The graph below shows the total number of articles in immune mechanisms in diabetic nephropathy across all publications each year (not limited to Nature Index journals).

Technical terms

Podocyte: specialised epithelial cell wrapping glomerular capillaries, critical for filtration barrier integrity.

Inflammasome: intracellular multiprotein complex that activates inflammatory caspases and cytokines in response to cellular stress.

Pyroptosis: form of programmed cell death driven by inflammasome activation, characterised by cell swelling and inflammatory cytokine release.

Chemokine: small secreted protein that directs migration of immune cells towards sites of inflammation.

Cytokine: broad category of signalling proteins, including interleukins and interferons, that regulate immune responses.

NF-κB: transcription factor complex central to the regulation of genes involved in inflammation and cell survival.

References

1. Interleukin 17A promotes diabetic kidney injury. Scientific Reports (2019).
2. T cells and their products in diabetic kidney disease. Frontiers in Immunology (2023).
3. Advances in understanding and treating diabetic kidney disease: focus on tubulointerstitial inflammation mechanisms. Frontiers in Endocrinology (2023).
4. Renal expression of cytokines and chemokines in diabetic nephropathy. BMC Nephrology (2020).
5. Mesenchymal stem cells alleviate rat diabetic nephropathy by suppressing CD103+ DCs‐mediated CD8+ T cell responses. Journal of Cellular and Molecular Medicine (2020).
6. Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy. International Journal of Molecular Sciences (2020).
7. Immune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target. Frontiers in Immunology (2022).